Impairments in Brain-to-Blood Transport of Amyloid-β and Reabsorption of Cerebrospinal Fluid in an Animal Model of Alzheimer's Disease are Reversed by Antisense Directed Against Amyloid-β Protein Precursor
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The blood-brain barrier (BBB) influences brain levels of amyloid-β (Aβ) by transporting Aβ out of the brain (efflux) and by the reabsorption of cerebrospinal fluid (CSF) into the blood stream (bulk flow). In Alzheimer's disease (AD) and normal aging, unknown factors impair Aβ efflux and bulk flow in aging and in AD. These impairments have been proposed as mechanisms by which the Aβ burden in brain can increase. Impairment in Aβ efflux occurs in animal models of AD, including the aged SAMP8 mouse. Here, we show that CSF reabsorption is also reduced by about 50% in SAMP8 mice (p < 0.05). We then determined whether an antisense directed at the Aβ region of the amyloid-β protein precursor (AβPP) and previously shown to decrease brain levels of AβPP and to reverse the cognitive impairments of the SAMP8 mouse was able to reverse these impairments. We found that the antisense restored both the CSF reabsorption, more than doubling the rate of efflux, and the saturable efflux of Aβ. These findings suggest that AβPP/Aβ itself contributes to the impairments in bulk flow and saturable efflux of Aβ and that reduction of AβPP/Aβ levels can restore normal function of the BBB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 2×
“Two BBB transporters have been implicated in A efflux, LRP-1 and P-gp [6] [7] [12] [13].”
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · cited 1×
“Amyloid- (A ) has increasingly emerged as a major candidate in the pathophysiology of Alzheimer’s disease (AD) [1].”
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563 · cited 2×
“Two BBB transporters have been implicated in A efflux, LRP-1 and P-gp [6] [7] [12] [13].”
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Farr, S. A., Poon, H. F., Dogrukol‐Ak, D., Drake, J., Banks, W. A., Eyerman, E., Butterfield, D. A., & Morley, J. E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01580.x · Cited by 459 · cited 1×
“Furthermore, the antioxidant alpha lipoic acid reverses both the cognitive impairments and the oxidative stress seen in the SAMP8 [40, 53].”
Self-citationClearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
Ghersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020880.x · Cited by 222 · cited 1×
“A is cleared from brain by saturable and nonsaturable mechanisms [5] [6] [7] [8] [9] [10] [11].”
Clearance of amyloid β-peptide from brain: transport or metabolism?
Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., & Frangione, B. (2000) · Nature Medicine · doi:10.1038/77397 · Cited by 186 · cited 1×
“E-mail: wabanks1@uw.edu. its clearance from brain [2] [3] [4].”
Fate of leptin after intracerebroventricular injection into the mouse brain
Maness, L. M., Kastin, A. J., Farrell, C. L., & Banks, W. A. (1998) · Endocrinology · doi:10.1210/endo.139.11.6319 · Cited by 119
Self-citation
Cited by
From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Self-citationPlasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
“α-Syn (rPeptide, Athens, GA, USA) was radioactively labeled with Na(125)I (Perkin Elmer, Waltham, MA, USA) by the chloramine-T (SigmaAldrich, St Louis, MO, USA) method [6], and then purified using a Sephadex G-10 column (Sigma-Aldrich).”
MethodSelf-citationBlood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Self-citationAmyloid‐β efflux from the central nervous system into the plasma
Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller‐Thomas, M. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24270 · Cited by 254
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184
Self-citation
Metadata
- Authors
- Banks, W. A., Kumar, V. B., Farr, S. A., Nakaoke, R., Robinson, S. M., & Morley, J. E.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-03-21
- Volume
- 23
- Issue
- 4
- Pages
- 599-605
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W69739385
- Cited by
- 35
- References
- 10
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.